Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lixte Biotechnology Holdings, Inc. (LIXTW) trades at $0.0221. Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for LIXTW: LIXTW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LIXTW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LIXTW: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Lixte Biotechnology Holdings, Inc. (LIXTW) Healthcare & Pipeline Overview
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in cancer drug development, with a focus on its lead product candidate, LB-100. The company is currently conducting Phase 1b and Phase 1b/2 clinical trials in combination with other drugs, targeting various cancers, including metastatic colorectal cancer, advanced soft tissue sarcoma, and ovarian clear cell carcinoma.
What Is the Investment Thesis for LIXTW?
Lixte Biotechnology Holdings, Inc. presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of LB-100. Positive results from ongoing Phase 1b and Phase 1b/2 clinical trials could serve as significant catalysts, potentially leading to partnerships or acquisitions. However, the company's negative Return on Equity (ROE) of -130.1% and negative Free Cash Flow (FCF) of $-0.00B highlight the financial challenges inherent in drug development. The company's beta of 0.89 suggests a slightly lower volatility compared to the market. Investors should closely monitor clinical trial outcomes and the company's ability to secure funding to sustain operations. The absence of a dividend reflects the company's focus on reinvesting capital into research and development.
Based on FMP financials and quantitative analysis
LIXTW Key Highlights
LB-100 is in Phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.
- LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion.
- LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
- The company has a clinical trial research agreement with the Netherlands Cancer Institute.
- Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Who Are LIXTW's Competitors?
LIXTW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LIXTW's Key Strengths?
Proprietary drug candidate (LB-100).
- Ongoing clinical trials.
- Collaborations with research institutions.
- Focus on novel cancer targets.
What Are LIXTW's Weaknesses?
Limited financial resources.
- Dependence on a single drug candidate.
- Early stage of development.
- Small number of employees.
What Could Drive LIXTW Stock Higher?
Data releases from ongoing Phase 1b and Phase 1b/2 clinical trials of LB-100.
- Potential for new strategic partnerships or collaborations.
- Securing additional funding to support clinical development.
What Are the Key Risks for LIXTW?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of LB-100 in clinical trials.
- Regulatory delays or rejection.
- Competition from other cancer therapies.
- Limited financial resources.
What Are the Growth Opportunities for LIXTW?
- Expansion of LB-100's Clinical Applications: Lixte has the opportunity to expand the clinical applications of LB-100 beyond its current trials. This could involve exploring its efficacy in treating other types of cancer or in combination with different therapeutic agents. The market for novel cancer therapies is substantial, with potential revenues in the billions of dollars annually for successful drugs. This expansion would require further clinical trials and regulatory approvals, with a timeline of several years.
- Strategic Partnerships and Collaborations: Lixte can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of LB-100. These partnerships could provide access to funding, expertise, and distribution networks. The value of such partnerships can range from millions to billions of dollars, depending on the stage of development and the potential market for the drug. The timeline for establishing these partnerships is ongoing.
- Securing Additional Funding: Lixte needs to secure additional funding to support its ongoing clinical trials and research and development activities. This could involve raising capital through equity offerings, debt financing, or grants. The amount of funding required will depend on the company's burn rate and the progress of its clinical programs. The timeline for securing funding is ongoing.
- Out-licensing or Acquisition of LB-100: Lixte could out-license or be acquired by a larger pharmaceutical company seeking to add LB-100 to its portfolio. This would provide Lixte with a significant upfront payment and potential royalties on future sales of the drug. The value of such a transaction could range from hundreds of millions to billions of dollars, depending on the clinical data and market potential of LB-100. The timeline for this is uncertain.
- Advancing LB-100 Through Clinical Trials: The most significant growth opportunity for Lixte lies in successfully advancing LB-100 through clinical trials. Positive results from these trials would increase the value of the drug and make it more attractive to potential partners or acquirers. The timeline for completing these trials is several years, and the outcome is uncertain.
What Threats Does LIXTW Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expiration.
What Are LIXTW's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating safety and efficacy.
- Collaborative relationships with leading cancer research institutions.
- Expertise in identifying novel cancer targets.
What Does LIXTW Do?
Founded in 2005 and based in Pasadena, California, Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying targets for cancer drug development and commercializing cancer therapies. The company's primary focus is on its lead product candidate, LB-100, which is currently undergoing several Phase 1b and Phase 1b/2 clinical trials. These trials explore LB-100's efficacy in combination with other drugs for treating various cancers. Specifically, LB-100 is being tested in conjunction with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer, with doxorubicin for advanced soft tissue sarcoma, and with dostarlimab for ovarian clear cell carcinoma. Lixte has established collaborative research agreements with institutions like the Netherlands Cancer Institute and the Spanish Sarcoma Group, furthering its research and development efforts. The company's strategy involves identifying novel cancer targets and developing therapies that can improve patient outcomes, positioning it within the competitive biotechnology landscape.
What Products and Services Does LIXTW Offer?
- Identifies targets for cancer drug development.
- Develops cancer therapies.
- Commercializes cancer therapies.
- Conducts Phase 1b clinical trials for LB-100 combined with Atezolizumab for metastatic colorectal cancer.
- Conducts Phase 1b clinical trials for LB-100 combined with doxorubicin for advanced soft tissue sarcoma.
- Conducts Phase 1b/2 clinical trials for LB-100 combined with dostarlimab for ovarian clear cell carcinoma.
How Does LIXTW Make Money?
- Develops and patents novel cancer therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks partnerships with larger pharmaceutical companies for commercialization.
- Potentially out-licenses or sells its drug candidates to generate revenue.
What Industry Does LIXTW Operate In?
Lixte Biotechnology Holdings, Inc. operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The industry is driven by the increasing global demand for innovative cancer therapies. Companies like Lixte face competition from both established pharmaceutical giants and other emerging biotech firms. Success hinges on the ability to identify novel drug targets, demonstrate clinical efficacy, and navigate the complex regulatory landscape.
Who Are LIXTW's Key Customers?
- Pharmaceutical companies seeking to acquire or license novel cancer therapies.
- Patients with cancer who may benefit from Lixte's therapies.
- Healthcare providers who prescribe cancer treatments.
Company Profile
Lixte Biotechnology Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pasadena, US. The company is led by CEO Geordan G. Pursglove. LIXTW has traded publicly since 2020.
Financial Health
Lixte Biotechnology Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
LIXTW Financials
Bull Case vs Bear Case
Bull Case
- LIXTW insiders seem to be accumulating shares, suggesting they see long-term value that the market isn't fully appreciating.
- The social trading community shows growing interest in LIXTW's potential, indicating increased awareness and positive buzz.
- LIXTW's approach to cancer treatment is gaining traction, with some viewing it as a potential game-changer.
- There's a sense that LIXTW is undervalued, with some believing its current market perception doesn't reflect its true potential.
Bear Case
- Despite positive sentiment, LIXTW faces significant competition in the biotech space, making it difficult to stand out.
- The social trading community also expresses concerns about LIXTW's ability to scale up and deliver on its promises.
- Market perception of LIXTW is still largely speculative, with many waiting for more concrete results before fully buying in.
- LIXTW's research and development is still in early stages, meaning it could be years before it generates significant revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LIXTW Latest News
No recent news available for LIXTW.
LIXTW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LIXTW.
Price Targets
Wall Street price target analysis for LIXTW.
LIXTW MoonshotScore
What does this score mean?
The MoonshotScore rates LIXTW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Common Questions About LIXTW (Healthcare)
What does Lixte Biotechnology Holdings, Inc. do?
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer therapies. Their primary asset is LB-100, a drug candidate currently undergoing Phase 1b and Phase 1b/2 clinical trials in combination with other drugs for various cancers, including metastatic colorectal cancer, advanced soft tissue sarcoma, and ovarian clear cell carcinoma.
What do analysts say about LIXTW stock?
As of 2026-03-16, there is no AI analysis available for LIXTW. Given its status as a clinical-stage biopharmaceutical company, valuation is highly dependent on the success of LB-100's clinical trials. Investors should closely monitor clinical trial data releases and the company's ability to secure funding.
What are the main risks for LIXTW?
The primary risks for Lixte Biotechnology Holdings, Inc. are related to the clinical development of LB-100. Failure to demonstrate safety and efficacy in clinical trials would significantly impact the company's value. Regulatory hurdles and competition from established pharmaceutical companies also pose significant risks.
What are the key factors to evaluate for LIXTW?
Evaluate LIXTW on fundamentals, analyst consensus, and risk factors. Lixte Biotechnology Holdings, Inc. presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. Not financial advice.
How frequently does LIXTW data refresh on this page?
LIXTW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LIXTW's recent stock price performance?
Lixte Biotechnology Holdings, Inc. (LIXTW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidate (LB-100). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LIXTW overvalued or undervalued right now?
Lixte Biotechnology Holdings, Inc. (LIXTW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LIXTW before investing?
Before investing in Lixte Biotechnology Holdings, Inc. (LIXTW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- AI analysis is pending and may provide further insights.